[1]陈世晞 陈骏 席玮 徐卫东 尹国文 徐清宇. TACE联合分子靶向药索拉菲尼治疗晚期肝癌远期疗效观察[J].介入放射学杂志,2011,(12):958-960.
　CHEN Shi-xi,CHEN Jun,XI Wei,et al. Transcatheter arterial chemoembolization combined with molecule-targeted sorafenib for the treatment of advanced hepatocelluar carcinoma: observation of its long-term efficacy[J].journal interventional radiology,2011,(12):958-960.
点击复制

 TACE联合分子靶向药索拉菲尼治疗晚期肝癌远期疗效观察()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2011年12期
页码:
958-960
栏目:
肿瘤介入
出版日期:
2011-12-30

文章信息/Info

Title:
 Transcatheter arterial chemoembolization combined with molecule-targeted sorafenib for the treatment of advanced hepatocelluar carcinoma: observation of its long-term efficacy
作者:
 陈世晞 陈骏 席玮 徐卫东 尹国文 徐清宇
210009  南京 江苏省肿瘤医院介入科
Author(s):
CHEN Shi-xi;  CHEN Jun;  XI Wei;  XU Wei-dong;  YIN Guo-wen;  XU Qing-yu.
 Department of Interventional Radiology, Jiangsu Provincial Cancer Hospital, Nanjing 210009, China
关键词:
 ; 肝动脉灌注化疗栓塞术;  索拉菲尼; 晚期肝癌
分类号:
R735.7
文献标志码:
A
摘要:
 目的 评价经肝动脉灌注化疗栓塞术联合分子靶向药物甲磺酸索拉菲尼治疗晚期肝细胞肝癌的临床疗效和不良反应。 方法 2007年6月至2009年5月，江苏省肿瘤医院介入科收治的30例晚期肝细胞肝癌患者，采用经肝动脉灌注化疗栓塞术（TACE）或单纯动脉灌注化疗，术中用药为氟脲苷1.0g，羟基喜树碱20mg，吡柔比星30mg，碘油栓塞肿瘤供血动脉。口服甲磺酸索拉菲尼（多吉美），起始剂量400mg，每日两次，治疗过程中根据不良反应情况调整用量。每6-8周全面复查一次，评价肝功能，治疗效果（CT复查、术中DSA等）和不良反应。用SPSS13.0软件统计计算中位，平均生存时间和无疾病进展。结果 至2009年12月，30名患者均达到临床评价要求，无中途停药。死亡26例，存活4例。口服索拉菲尼相关不良反应发生率83.3%。主要不良反应为：手足皮肤反应、腹泻与高血压。无疾病进展期内DSA术中造影可见肿瘤血管较服药前稀疏，纤细。经统计学分析，中位生存期38周，平均生存期41周，无疾病进展时间18周。结论 晚期肝癌，经肝动脉灌注化疗栓塞术联合分索拉菲尼口服治疗，能够明显延长患者生存时间，且无严重不良反应发生。

参考文献/References:

 [1]蔡 琳，Binh Y, Donald MP, et al．亚太若干地区恶性肿瘤流行趋势分析[J]．肿瘤，2004，24：422-426．
[2]Llovet JM. Updated treatment approach to hepatocellular carcinoma[J]. J Gastroenterol, 2005, 40: 225-235.
[3]Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma[J]. Hepatology, 2005, 42: 1208-1236.
[4]Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008[J]. J Hepatol, 2008, 48 Suppl 1: S20-S37.
[5]Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis[J]. Cancer Res, 2004, 64: 7099-7109.
[6]Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5[J]. Cancer Res, 2006, 66: 11851-11858.
[7]Gu FM, Li QL, Gao Q, et al. Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3[J]. World J Gastroenterol, 2011, 17: 3922-3932.
[8]Abou-Alfa GK, Amadori D, Santoro A, et al. Safety and efficacy of sorafenib in patients with hepatocellular carcinoma (HCC) and Child-Pugh A versus B cirrhosis[J]. Gastrointest Cancer Res, 2011, 4: 40-44.
[9]Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008, 359: 378-390.

相似文献/References:

[1]张 琳,黄学全,王健,等.自主研发电化学治疗同轴电极与传统针式电极电解效应的对比研究[J].介入放射学杂志,2012,(02):148.
　ZHANG Lin,HUANG Xue-quan,WANG Jian,et al.The electrolytic effect in electrochemotherapy: a comparative study between self-prepared coaxial electrode and conventional needle electrode[J].journal interventional radiology,2012,(12):148.
[2]赵 玮,王伟中,陈莹,等.耳部动静脉畸形供血动脉的血管造影研究[J].介入放射学杂志,2012,(02):103.
　ZHAO Wei,WANG Wei-zhong,CHEN Ying,et al.Angiographic findings of the feeding arteries of auricular arteriovenous malformations[J].journal interventional radiology,2012,(12):103.
[3]邹俊民,龙世娟,张振明. 改良髂内动脉化疗联合放疗治疗Ⅲ~Ⅳa期 子宫颈癌32例[J].介入放射学杂志,2012,(02):123.
　ZOU Jun-min,LONG Shi-Juan,ZHANG Zheng-ming..Improved internal iliac artery chemotherapy combined with radiotherapy for the treatment of stage Ⅲ-Ⅳa cervical cancers[J].journal interventional radiology,2012,(12):123.
[4]王昌明,李 选,宋世兵,等.肝门部胆道引流管折叠技术在肝移植后胆道非吻合口狭窄治疗中的应用[J].介入放射学杂志,2012,(02):136.
　WANG Chang-ming,LI Xuan,SONG Shi-bing,et al.The application of biliary catheter folding technique in the treatment of hilar nonanastomotic biliary strictures after orthotopic liver transplantation[J].journal interventional radiology,2012,(12):136.
[5]赵玉峰,孙玉琴,韩晓静,等. 输卵管介入再通术后受孕时机的研究[J].介入放射学杂志,2012,(02):158.
　ZHAO Yu-feng,SUN Yu-qin,HAN Xiao-jing,et al.The optimal time for conception after fallopian tube recanalization therapy[J].journal interventional radiology,2012,(12):158.
[6]含 笑,曹建民,史东宏,等.吉西他滨、顺铂动静脉联合化疗治疗晚期非小细胞肺癌的近期疗效分析[J].介入放射学杂志,2012,(02):119.
　HAN Xiao,CAO Jian-min,SHI Dong-hong,et al.Bronchial artery infusion of Gemcitabine and Cisplatin combined with systemic chemotherapy for advanced non-small cell lung cancer: its short-term efficacy[J].journal interventional radiology,2012,(12):119.
[7]姚雪松,李 槐.不可手术切除的肝细胞癌的疗效评价标准——改良ＲＥＣＩＳＴ标准更可靠[J].介入放射学杂志,2012,(03):177.
　. Ｔｈｅｒａｐｅｕｔｉｃ ｅｖａｌｕａｔｉｏｎ ｃｒｉｔｅｒｉｏｎ ｏｆ ｉｎｏｐｅｒａｂｌｅ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ： ｍｏｄｉｆｉｅｄ ＲＥＣＩＳＴ ａｓ ａ ｍｏｒｅ ｒｅｌｉａｂｌｅ ｓｔａｎｄａｒｄ[J].journal interventional radiology,2012,(12):177.
[8]齐 立,李慎茂,俸军林,等. 动脉溶栓与机械碎栓联合动脉溶栓的对比分析[J].介入放射学杂志,2012,(03):180.
　,,et al. Ｃｏｍｐａｒｉｓｏｎ ｏｆ ｔｈｅ ｔｈｅｒａｐｅｕｔｉｃ ｅｆｆｉｃａｃｙ ｂｅｔｗｅｅｎ ｓｉｍｐｌｅ ａｒｔｅｒｉａｌ ｔｈｒｏｍｂｏｌｙｓｉｓ ａｎｄ ｍｅｃｈａｎｉｃａｌ ｔｈｒｏｍｂｅｃｔｏｍｙ ｃｏｍｂｉｎｅｄ ｗｉｔｈ ａｒｔｅｒｉａｌ ｔｈｒｏｍｂｏｌｙｓｉｓ ｆｏｒ ａｃｕｔｅ ｃｅｒｅｂｒａｌ ｉｎｆａｒｃｔｉｏｎ ａｔ ｉｔｓ ｕｌｔｒａｅａｒｌｙ ｓｔａｇｅ[J].journal interventional radiology,2012,(12):180.
[9]石 潆,赵 卫,沈 进,等.脑动静脉畸形栓塞治疗术并发颅内出血的原因及处理[J].介入放射学杂志,2012,(03):185.
　,,et al.Ｉｎｔｒａｃｒａｎｉａｌ ｈｅｍｏｒｒｈａｇｅ ｄｕｅ ｔｏ ｅｍｂｏｌｉｚａｔｉｏｎ ｔｈｅｒａｐｙ ｆｏｒ ｃｅｒｅｂｒａｌ ａｒｔｅｒｉｏｖｅｎｏｕｓ ｍａｌｆｏｒｍａｔｉｏｎ： ｉｔｓ ｃａｕｓｅｓ ａｎｄ ｍａｎａｇｅｍｅｎｔ [J].journal interventional radiology,2012,(12):185.
[10]周 慷,李晓光,金征宇,等.清宫术前子宫动脉化疗栓塞术治疗瘢痕妊娠的疗效分析[J].介入放射学杂志,2012,(03):190.
　,,et al.Ｔｈｅｒａｐｅｕｔｉｃ ａｎａｌｙｓｉｓ ｏｆ ｂｉｌａｔｅｒａｌ ｕｔｅｒｉｎｅ ａｒｔｅｒｙ ｃｈｅｍｏｅｍｂｏｌｉｚａｔｉｏｎ ｐｅｒｆｏｒｍｅｄ ｂｅｆｏｒｅ ｕｔｅｒｉｎｅ ｄｉｌａｔｉｏｎ ａｎｄ ｃｕｒｅｔｔａｇｅ ｆｏｒ ｃｅｓａｒｅａｎ ｓｃａｒ ｐｒｅｇｎａｎｃｙ [J].journal interventional radiology,2012,(12):190.

备注/Memo

备注/Memo:
 收稿日期：2011-08-03
更新日期/Last Update: